Imunon (NASDAQ:IMNN) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Imunon (NASDAQ:IMNN) in a report released on Monday morning,Benzinga reports. D. Boral Capital currently has a $29.00 price target on the stock.

Several other research firms have also weighed in on IMNN. EF Hutton Acquisition Co. I upgraded shares of Imunon to a “strong-buy” rating in a report on Monday, September 23rd. HC Wainwright reduced their price objective on Imunon from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, November 11th.

Imunon Stock Performance

IMNN opened at $0.86 on Monday. Imunon has a 1 year low of $0.48 and a 1 year high of $3.65. The firm has a 50 day moving average price of $0.93 and a 200 day moving average price of $1.14. The company has a market cap of $12.41 million, a PE ratio of -0.45 and a beta of 2.14.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.